RT Book, Section
A1 Gruenberg, Katherine
A1 Guglielmo, B. Joseph
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193122117
T1 Rifamycins
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193122117
RD 2024/04/24
AB In  addition  to  its  use  as  a  primary  agent  in  the  treatment  of  active  and  latent  tuberculosis,  rifampin  is  used  as  an  adjunct  in  the  treatment  of  S  aureus  infections.  When  used  as  monotherapy,  rifampin  is  associated  with  rapid  emergence  of  resistance  in  staphylococci.  However,  when  added  to  other  primary  antistaphylococcal  agents,  rifampin  improves  outcomes  in  the  treatment  of  infected  prosthetic  hardware.  Due  to  its  rapid  bactericidal  activity,  rifampin  was  hypothesized  to  be  an  effective  adjunct  in  the  treatment  of  S  aureus  bacteremia  without  hardware  present.  However,  the  addition  of  rifampin  to  standard  therapy  for  the  treatment  of  S  aureus  bacteremia  does  not  improve  outcomes,  including  treatment  failure,  recurrence,  or  death.  Rifampin  is  also  effective  for  the  treatment  of  latent  tuberculosis  infection.